WS #15089
The biotech sector is seeing significant M&A activity and earnings beats. Xeris Biopharma shares jumped on reports that Lundbeck is interested in buying the company, while Iovance Biotherapeutics rallied 33% after raising its full-year revenue outlook. These developments highlight a selective bullishness in healthcare, driven by consolidation and strong operational performance, contrasting with the broader macro headwinds.
Biotech M&A and Earnings
The biotech sector is seeing significant M&A activity and earnings beats. Xeris Biopharma shares jumped on reports that Lundbeck is interested in buying the company, while Iovance Biotherapeutics rallied 33% after raising its full-year revenue outlook. These developments highlight a selective bullishness in healthcare, driven by consolidation and strong operational performance, contrasting with the broader macro headwinds.